Citations

Clear

3138 citation(s) found for "Smith, AM".

A phase II trial of pharmacological ascorbate, gemcitabine, and nabpaclitaxel for metastatic pancreatic cancer.
Smith, Brian J., Vollstedt, Sandy , Chandler, Meghan L. , Kasi, Pashtoon Murtaza , Bodeker, Kellie L. , Berg, Daniel , Chandrasekharan, Chandrikha , Sharif, Saima , Smith, Brian J., Brown, Heather A. , Cullen, Joseph J

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: TPS791-TPS791

10.1200/jco.2020.38.4_suppl.tps791 Get It

TPS791 Background: FOLFIRINOX or gemcitabine/nab-paclitaxel are both frontline chemotherapy options for patients with metastatic pancreas cancer. For most who cannot tolerate the triplet, the latter doublet is the preferred option. Through previous work by our group, pharmacologic ascorbate is known to synergize with gemcitabine; preliminary in vitro data from our group suggests a similar synergistic response with paclitaxel. Though ascorbate has been utilized in cancer therapy, few robust trials have investigated intravenous delivery of ascorbate to deliver plasma concentrations that are cytotoxic to tumor cells. Our prior studies have demonstrated ascorbate induces oxidative stress and cytotoxicity in pancreatic cancer cells; this cytotoxicity appears to be greater in tumor vs. normal cells. We hypothesize that production of hydrogen peroxide mediates the increased susceptibility of pancreatic cancer cells to ascorbate-induced metabolic oxidative stress, resulting in improved treatment outcomes, which has led to the development of the clinical trial (NCT02905578). Methods: All participants receive gemcitabine (1000 mg/m2 weekly) and nab-paclitaxel (125 mg/m2) on cycle days 1, 8, and 15 of a 28-day cycle. Participants are randomized to ± pharmacologic ascorbate (75-gram infusion 3x weekly) in addition to chemotherapy. Study therapy continues until tumor progression. The primary objective is to determine overall survival in patients when treated with combination gemcitabine, nab-Paclitaxel and high-dose ascorbic acid compared to gemcitabine and nab-paclitaxel in patients with non-resectable pancreatic cancer. Secondary objectives include determining objective response rate as well as progression free survival using RECIST 1.1 criteria employing a blinded reviewer for RECIST measurements. The study opened to accrual in 2018 with a goal of enrolling 65 participants. Oversight.Study is conducted under IND 105715 (J. Cullen, sponsor). The University of Iowa Biomedical IRB (IRB-01) serves as the IRB of record. Clinical trial information: NCT02905578.
Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies.
Shafique, Michael , Fisher, Terrence L. , Pastore, Desa Rae E. , Mallow, Crystal, Smith, Ernest, Chin, Kevin M. , Baumgart, Megan , Gabrail, Nashat , Lou, Yanyan, Zauderer, Maurice , Evans, Elizabeth E. , Leonard, John E. , Schröder, Andreas, Beck, J. Thaddeus , Govindan, Ramaswamy , Sanborn, Rachel E , Spira, Alexander I. , Seetharamu, Nagashree , Mansfield, Aaron S. , Goldman, Jonathan W.

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 5_suppl | Pages: 75-75

10.1200/jco.2020.38.5_suppl.75 Get It

75 Background: Despite progress of immune checkpoint therapies, many cases of non-small cell lung cancer (NSCLC) are refractory or acquire resistance to current therapies. Antibody blockade of semaphorin 4D (SEMA4D, CD100) can overcome resistance mechanisms of immune exclusion and myeloid suppression. Importantly, combinations of anti-SEMA4D with various immunotherapies enhanced T cell infiltration and activity, as well as durable tumor regression in preclinical models. Pepinemab (VX15/2503) is a first-in-class humanized monoclonal antibody targeting SEMA4D. Methods: The CLASSICAL-Lung clinical trial (NCT03268057) evaluates the combination of pepinemab with anti-PD-L1 antibody avelumab to couple beneficial modifications of the immune microenvironment via pepinemab with immune activation via checkpoint inhibition. This ongoing study evaluates the safety, tolerability and efficacy of the combination in patients with advanced (stage IIIB/IV) NSCLC, including immunotherapy-naïve (ION) patients and patients whose tumors progressed during or following immunotherapy (IOF). Results: The combination was well tolerated with no major safety signals identified. Among 29 evaluable IOF patients, two experienced confirmed partial response (PR) with 63% and 52% tumor reduction on study following acquired resistance to prior treatment with pembrolizumab, 15 additional patients experienced stable disease, and at least 5 patients with durable clinical benefit of ≥ 23 weeks. Among 21 evaluable ION patients, 5 experienced PR, clinical benefit ≥ 1 year was observed in 3 patients, and Disease Control Rate was 81%. Analysis of pre- and on-treatment biopsies demonstrated increased CD8+ T cell density correlating with response, reduction or elimination of tumor in 11/13 biopsies from subjects with PR or SD. Conclusions: Interim analysis suggests the combination of pepinemab plus avelumab is well tolerated and shows initial clinical signals of antitumor activity. Updated clinical response data (minimum of 6 mo. follow-up), as well as additional immunophenotyping of both inflammatory and suppressive myeloid cells will be presented. Clinical trial information: NCT03268057.
Chromatin-Modifying Enzymes in T Cell Development
Shapiro, Michael J. , Shapiro, Virginia Smith , Shapiro, Michael J.

Mayo Clinic

Annual Review of Immunology | January 28, 2020 | Volume: 38 | Issue: 1 | Pages: 397-419

10.1146/annurev-immunol-092719-082622 | PMID 31990620 Get It

T cell development involves stepwise progression through defined stages that give rise to multiple T cell subtypes, and this is accompanied by the establishment of stage-specific gene expression. Changes in chromatin accessibility and chromatin modifications accompany changes in gene expression during T cell development. Chromatin-modifying enzymes that add or reverse covalent modifications to DNA and histones have a critical role in the dynamic regulation of gene expression throughout T cell development. As each chromatin-modifying enzyme has multiple family members that are typically all coexpressed during T cell development, their function is sometimes revealed only when two related enzymes are concurrently deleted. This work has also revealed that the biological effects of these enzymes often involve regulation of a limited set of targets. The growing diversity in the types and sites of modification, as well as the potential for a single enzyme to catalyze multiple modifications, is also highlighted.
Survey of equal contributions in biomedical research publications
Resnik, David B. , Smith, Elise , Master, Zubin , Shi, Min , Master, Zubin

Mayo Clinic

Accountability in Research | January 27, 2020 | Volume: 27 | Issue: 3 | Pages: 115-137

10.1080/08989621.2020.1722947 | PMID 31986059 Get It

Pearls for Interpreting Neurosurgical Systematic Reviews and Meta-Analyses: Lessons From a Collaborative Effort
Lu, Victor M. , Graffeo, Christopher S. , Perry, Avital , Link, Michael J., Meyer, Fredric B. , Dawood, Hassan Y. , Mekary, Rania A. , Smith, Timothy R. , Link, Michael J.

Mayo Clinic

Neurosurgery | January 24, 2020 | Volume: 87 | Issue: 3 | Pages: 435-441

10.1093/neuros/nyaa027 | PMID 32140720 Get It

Abstract Systematic reviews and meta-analyses in the neurosurgical literature have surged in popularity over the last decade. It is our concern that, without a renewed effort to critically interpret and appraise these studies as high or low quality, we run the risk of the quality and value of evidence-based medicine in neurosurgery being misinterpreted. Correspondingly, we have outlined 4 major domains to target in interpreting neurosurgical systematic reviews and meta-analyses based on the lessons learned by a collaboration of clinicians and academics summarized as 4 pearls. The domains of (1) heterogeneity, (2) modeling, (3) certainty, and (4) bias in neurosurgical systematic reviews and meta-analyses were identified as aspects in which the authors’ approaches have changed over time to improve robustness and transparency. Examples of how and why these pearls were adapted were provided in areas of cranial neuralgia, spine, pediatric, and neuro-oncology to demonstrate how neurosurgical readers and writers may improve their interpretation of these domains. The incorporation of these pearls into practice will empower neurosurgical academics to effectively interpret systematic reviews and meta-analyses, enhancing the quality of our evidence-based medicine literature while maintaining a critical focus on the needs of the individual patients in neurosurgery.
Predictors of exercise capacity following septal myectomy in patients with hypertrophic cardiomyopathy
Smith, Joshua R. , Layrisse, Veronica, Medina‐Inojosa, José R. , Berg, Jessica, Ommen, Steve R. , Olson, Thomas P. , Berg, Jessica D, Smith, Joshua R , Medina-Inojosa, José R

Mayo Clinic

European Journal of Preventive Cardiology | January 22, 2020 | Volume: 27 | Issue: 10 | Pages: 1066-1073

10.1177/2047487319898106 | PMID 31967491 Get It

Aims Patients with hypertrophic obstructive cardiomyopathy (HOCM) have impaired exercise capacity. The gold standard therapy for patients with HOCM is septal myectomy surgery; however, changes in maximum oxygen uptake (VO2peak) following myectomy are variable, with VO2peak decreasing in some patients. Therefore, we evaluated changes in VO2peak following surgical myectomy to determine clinical predictors of those exhibiting decreased VO2peak post-myectomy. Methods HOCM patients ( N = 295) who performed symptom limited cardiopulmonary exercise testing prior to and following surgical myectomy were included for analysis. The VO2peak non-responder group ( n = 128) was defined as <0% change in VO2peak from pre- to post-myectomy. Step-wise regression models using demographics, clinical, and physiologic characteristics were created to determine predictors of hypertrophic cardiomyopathy patients in the VO2peak non-responder group. Results Independent predictors of the VO2peak non-responder group included higher pre-myectomy VO2peak (% predicted), older age, women, history of dyslipidemia, lack of cardiac rehabilitation enrollment, and lower body mass index (all p < 0.03). Forty-three (14.6%) patients reached the primary end-point of all-cause mortality during a median follow up of 11.25 years (interquartile range 6.94 to 16.40). After adjustment for age, sex, beta-blocker use, coronary artery disease history, and body mass index, the VO2peak non-responder group had greater risk of death compared with the VO2peak responder group (adjusted hazard ratio: 1.77, 95% confidence interval: 1.06–3.34, p = 0.01). Conclusion This large hypertrophic cardiomyopathy cohort demonstrated that demographic (i.e. female sex), lack of cardiac rehabilitation enrollment, and cardiovascular risk factors (i.e. history of dyslipidemia) are predictive of those patients that did not exhibit increases in VO2peak following septal myectomy surgery.
Strategies for effective physics plan and chart review in radiation therapy: Report of AAPM Task Group 275
Ford, Eric , Santos, L Fong de los, Greener, Anne, Kim, Grace Gwe‐Ya, Johnson, Jennifer L. , Johnson, Perry , Napolitano, Brian, Parker, S. , Schofield, Deborah , Smith, Koren, Yorke, Ellen , Wells, Michelle, de Los Santos, Luis Fong, Conroy, Leigh , Dong, Lei , Santos, Luis E. Fong de los, Mechalakos, James

Mayo Clinic

Medical Physics | January 22, 2020 | Volume: 47 | Issue: 6 | Pages: No page available

10.1002/mp.14030 | PMID 31967655 Get It

Background While the review of radiotherapy treatment plans and charts by a medical physicist is a key component of safe, high‐quality care, very few specific recommendations currently exist for this task. Aims The goal of TG‐275 is to provide practical, evidence‐based recommendations on physics plan and chart review for radiation therapy. While this report is aimed mainly at medical physicists, others may benefit including dosimetrists, radiation therapists, physicians and other professionals interested in quality management. Methods The scope of the report includes photon/electron external beam radiotherapy (EBRT), proton radiotherapy, as well as high‐dose rate (HDR) brachytherapy for gynecological applications (currently the highest volume brachytherapy service in most practices). The following review time points are considered: initial review prior to treatment, weekly review, and end‐of‐treatment review. The Task Group takes a risk‐informed approach to developing recommendations. A failure mode and effects analysis was performed to determine the highest‐risk aspects of each process. In the case of photon/electron EBRT, a survey of all American Association of Physicists in Medicine (AAPM) members was also conducted to determine current practices. A draft of this report was provided to the full AAPM membership for comment through a 3‐week open‐comment period, and the report was revised in response to these comments. Results The highest‐risk failure modes included 112 failure modes in photon/electron EBRT initial review, 55 in weekly and end‐of‐treatment review, 24 for initial review specific to proton therapy, and 48 in HDR brachytherapy. A 103‐question survey on current practices was released to all AAPM members who self‐reported as working in the radiation oncology field. The response rate was 33%. The survey data and risk data were used to inform recommendations. Discussion Tables of recommended checks are presented and recommendations for best practice are discussed. Suggestions to software vendors are also provided. Conclusions TG‐275 provides specific recommendations for physics plan and chart review which should enhance the safety and quality of care for patients receiving radiation treatments.
Assessment of hospital emergency medication kit use at a large academic medical center with automated dispensing machine technology
Smith, Bradley L. , Griffin, Monica G., Heyliger, Alexander , Ritchie, Brianne M., Smith, Bradley L

Mayo Clinic

American Journal of Health-System Pharmacy | January 21, 2020 | Volume: 77 | Issue: Supplement_1 | Pages: S8-S12

10.1093/ajhp/zxz294 | PMID 31961922 Get It

Abstract Purpose Hospital emergency medication kits (HEMKs) are used to provide certain critical medications in emergent situations, despite many technological advancements for patient safety and medication distribution. We sought to evaluate HEMK usage and analyze associated costs to identify and recommend process improvements. Methods Mayo Clinic in Rochester, MN, is a large multisite academic medical center with 2 hospital campuses and many ambulatory clinics. All documentation of the approximately 250 HEMKs in circulation was analyzed from January to November 2017. The primary outcome was HEMK use. Secondary outcomes included individual medication usage and associated costs. These data were then used to recommend process improvements. Results Of 880 HEMKs evaluated, 675 (76.7%) were used, resulting in expiration 23.3% of the time. A total of 1,024 emergency medications were used, most commonly for hypoglycemia. Many of these medications are also available in automated dispensing machines for patient care use. Cost analysis revealed an average annual cost of nearly $200,000 associated with HEMKs. The results of our analysis indicated little added benefit of HEMKs in the setting of automated dispensing machine optimization. Steps for HEMK retirement are described. Conclusion HEMKs offered little added benefit considering technological advancements that have been made in patient safety and medication distribution since their inception. Retirement of HEMKs is anticipated to increase pharmacy operational efficiency by using automated dispensing machine technology and appropriate emergency response protocols to ensure optimal patient care.
Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines
Allen, Timothy Craig, Attanoos, Richard , Borczuk, Alain , Burke, Louise , Cagle, Philip T., Đačić, Sanja , Guinee, Donald G., Raparia, Kirtee, Roden, Anja C. , Roy‐Chowdhuri, Sinchita , Sholl, Lynette M. , Beasley, Mary Beth , Roy-Chowdhuri, Sinchita , Hariri, Lida P. , Smith, Maxwell L. , Mino-Kenudson, Mari A. , Capelozzi, Vera Luíza , Churg, Andrew

Mayo Clinic

Annals of the American Thoracic Society | January 16, 2020 | Volume: 17 | Issue: 5 | Pages: 550-554

10.1513/annalsats.201910-801ps | PMID 31945306 Get It

Deep inspirations attenuate postprandial airway inflammation in college-aged adults with elevated baseline exhaled nitric oxide: A pilot study
Kurti, Stephanie P. , Smith, Joshua R. , Rosenkranz, Sara K. , Emerson, Sam R. , Edwards, Elizabeth S. , Jurrens, Kayla, Laughlin, A., Kurti, S P , Edwards, E S , Smith, Joshua R , Harms, Craig A.

Mayo Clinic

Experimental Lung Research | January 16, 2020 | Volume: 46 | Issue: 1-2 | Pages: 32-43

10.1080/01902148.2020.1713923 | PMID 31941389 Get It